Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Capital Expenditures: 2020-2024

Historic Capital Expenditures for Immuneering (IMRX) over the last 4 years, with Dec 2024 value amounting to $9,356.

  • Immuneering's Capital Expenditures fell 94.53% to $9,356 in Q4 2024 from the same period last year, while for Dec 2024 it was $84,875, marking a year-over-year decrease of 75.24%. This contributed to the annual value of $84,875 for FY2024, which is 75.24% down from last year.
  • Immuneering's Capital Expenditures amounted to $9,356 in Q4 2024, which was up 77.60% from $5,268 recorded in Q3 2024.
  • In the past 5 years, Immuneering's Capital Expenditures registered a high of $393,134 during Q3 2022, and its lowest value of $5,268 during Q3 2024.
  • Its 3-year average for Capital Expenditures is $97,509, with a median of $63,226 in 2022.
  • Its Capital Expenditures has fluctuated over the past 5 years, first spiked by 3,364.96% in 2022, then tumbled by 94.53% in 2024.
  • Quarterly analysis of 5 years shows Immuneering's Capital Expenditures stood at $38,058 in 2020, then crashed by 65.70% to $13,052 in 2021, then spiked by 430.97% to $69,302 in 2022, then soared by 146.63% to $170,918 in 2023, then crashed by 94.53% to $9,356 in 2024.
  • Its Capital Expenditures stands at $9,356 for Q4 2024, versus $5,268 for Q3 2024 and $32,773 for Q2 2024.